In a regulatory filing, Acadia Pharmaceuticals (ACAD) disclosed that on January 13, the company presented at the J.P. Morgan Healthcare Conference announcing, among other things, that it anticipates 2025 net sales will exceed $1B, consistent with prior guidance.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals price target raised to $40 from $35 at UBS
- Acadia Pharmaceuticals price target raised to $36 from $33 at Citi
- Acadia Pharmaceuticals price target raised to $34 from $29 at Needham
- Acadia Pharmaceuticals price target raised to $37 from $32 at H.C. Wainwright
- Acadia Pharmaceuticals announces FDA approval of Daybue Stix for oral solution